Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Feraflu is an over-the-counter (OTC) combination medication developed by Faromed for the symptomatic treatment of the common cold and influenza. As a small molecule product, it typically combines an analgesic and antipyretic agent, such as paracetamol (acetaminophen), with a nasal decongestant, such as phenylephrine hydrochloride. Paracetamol provides relief from fever and pain by inhibiting prostaglandin synthesis in the central nervous system, while phenylephrine acts as a selective alpha-1 adrenergic receptor agonist to reduce nasal congestion by inducing vasoconstriction in the nasal mucosa. The product is part of Faromed's Cold and Flu range and is designed for the rapid relief of upper respiratory symptoms including aches, fever, and congestion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Feraflu.